Clinical TrialJun 29, 2026, 08:41 AM
Evommune EVO756 Phase 2b CSU trial fails primary endpoint
AI Summary
Evommune announced top-line results from its Phase 2b trial evaluating EVO756 for moderate-to-severe chronic spontaneous urticaria (CSU). The study did not meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. Consequently, the company plans to cease development of EVO756 for CSU. However, Evommune will continue to evaluate EVO756 for other indications, including Atopic Dermatitis and Migraine, with Phase 2b data for Atopic Dermatitis expected in Q3 2026. The company also highlighted positive Phase 2a data for EVO301 in Atopic Dermatitis and a strong cash position through 2028.
Key Highlights
- EVO756 Phase 2b trial for chronic spontaneous urticaria (CSU) did not meet its primary endpoint.
- The study did not show efficacy at 12 weeks for any dose of EVO756 in CSU patients.
- Evommune plans to cease development of EVO756 for CSU.
- The company will continue to evaluate EVO756 in additional indications like Atopic Dermatitis and Migraine.
- Top-line Phase 2b data for EVO756 in Atopic Dermatitis is expected in Q3 2026.
- Screening has begun for a Phase 2b trial of EVO756 in migraine prophylaxis.
- Evommune reported positive Phase 2a proof-of-concept data for EVO301 in Atopic Dermatitis.
- The company has a strong cash position supporting operations through 2028.
Price Impact
More from EVMN